Ixico 

Headquartered in London, United Kingdom, IXICO plc specializes in providing sophisticated data analytics services to the global biopharmaceutical industry. Its operational reach extends across the United Kingdom, Switzerland, the Netherlands, Ireland, other European countries, and the United States. The company's core offerings encompass the entire lifecycle of clinical study data, from its meticulous acquisition and analysis to its systematic management and comprehensive reporting. IXICO features proprietary technologies like Assessa, a robust, web-based digital platform that facilitates precise patient selection for trials and supports vital post-marketing surveillance. Another significant platform is TrialTracker, which offers specialized imaging services. This system is engineered to streamline the intricate imaging workflow, overseeing everything from image ingestion and quality assurance to expert reading, analysis, reporting, and secure data transfer. IXICO focuses its expertise primarily on neurological disorders. These include major conditions such as Alzheimer's, Parkinson's, and Huntington's, alongside Multiple Sclerosis and other demyelinating conditions, Progressive Supranuclear Palsy, and a range of other rare neurological diseases. Beyond its platform offerings, IXICO provides a comprehensive suite of services. These include specialized analytics for drug development, dedicated imaging operation support, and expert consultancy. Furthermore, it delivers complete, 'end-to-end' project support for clinical trials, encompassing initial trial design and consultation, robust project management, the establishment and oversight of imaging sites, comprehensive data management, meticulous reading and analysis, and guidance through the complex regulatory pathway. Established in 1995, IXICO plc continues to innovate within its field.